These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15051746)

  • 21. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of ximelagatran.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition.
    Kereiakes DJ
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S4-11. PubMed ID: 15619615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No influence of food on the pharmacokinetics, pharmacodynamics or tolerability of the 24mg and 36mg oral tablet formulations of ximelagatran.
    Ersdal E; Schützer KM; Lönnerstedt C; Ohlsson L; Wall U; Eriksson UG
    Clin Drug Investig; 2005; 25(7):425-33. PubMed ID: 17532684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
    Johansson LC; Andersson M; Fager G; Gustafsson D; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):475-84. PubMed ID: 12739985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
    Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
    Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy.
    Bååthe S; Hamrén B; Karlsson MO; Wollbratt M; Grind M; Eriksson UG
    Clin Pharmacokinet; 2006; 45(8):803-19. PubMed ID: 16884319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N
    Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
    Sarich TC; Eriksson UG; Mattsson C; Wolzt M; Frison L; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):300-5. PubMed ID: 11858491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
    Wolzt M; Wollbratt M; Svensson M; Wåhlander K; Grind M; Eriksson UG
    Eur J Clin Pharmacol; 2003 Oct; 59(7):537-43. PubMed ID: 12955372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Johansson S; Cullberg M; Eriksson UG; Elg M; Dunér K; Jensen E; Wollbratt M; Wåhlander K
    Int J Clin Pharmacol Ther; 2011 Apr; 49(4):258-67. PubMed ID: 21429440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.
    Eriksson UG; Bredberg U; Hoffmann KJ; Thuresson A; Gabrielsson M; Ericsson H; Ahnoff M; Gislén K; Fager G; Gustafsson D
    Drug Metab Dispos; 2003 Mar; 31(3):294-305. PubMed ID: 12584156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ximelagatran--a promising new drug in thromboembolic disorders.
    Petersen P
    Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
    Mattsson C; Sarich TC; Carlsson SC
    Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
    Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
    Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ximelagatran (AstraZeneca).
    Hopfner R
    Curr Opin Investig Drugs; 2002 Feb; 3(2):246-51. PubMed ID: 12020054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
    Christersson C; Oldgren J; Bylock A; Wallentin L; Siegbahn A
    J Thromb Haemost; 2005 Oct; 3(10):2245-53. PubMed ID: 16194202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.